403 related articles for article (PubMed ID: 35072623)
1. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
2. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
5. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
6. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
7. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
11. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib Versus Dabrafenib + Trametinib in
Busaidy NL; Konda B; Wei L; Wirth LJ; Devine C; Daniels GA; DeSouza JA; Poi M; Seligson ND; Cabanillas ME; Sipos JA; Ringel MD; Eisfeld AK; Timmers C; Shah MH
Thyroid; 2022 Oct; 32(10):1184-1192. PubMed ID: 35658604
[No Abstract] [Full Text] [Related]
13. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
14. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
17. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
18. Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF
Martín-Soberón MC; Ruiz S; De Velasco G; Yarza R; Carretero A; Castellano D; Sepúlveda-Sánchez JM
J Med Case Rep; 2021 Mar; 15(1):109. PubMed ID: 33653337
[TBL] [Abstract][Full Text] [Related]
19. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
[TBL] [Abstract][Full Text] [Related]
20. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
Dimou A; Barron G; Merrick DT; Kolfenbach J; Doebele RC
BMC Cancer; 2020 Mar; 20(1):177. PubMed ID: 32131760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]